LH at a glance
Labcorp (LH, SEC CIK 920148) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 30, 2026 and Form 4 insider filings as recently as September 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Labcorp (LH) reported revenue of $14.0 billion (up 7.2% from FY2024) and net income of $876.5 million. Diluted EPS was $10.46.
- As of June 30, 2026, 42 institutional investment managers tracked by SignalX reported holding Labcorp (LH) shares worth $8.7 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by ANDERSON KERRII B on August 17, 2026 of 3,000 shares at $318.02 per share.
- In the last 90 days, LH insiders reported 0 open-market purchases ($0) and 5 open-market sales ($3.2M) on Form 4, a net sale of $3.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $14.0B
- +7.2% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$3.2M
- 13F holders
- 42 funds
- $8.7B · +4 vs prior quarter
- Latest 8-K
- Sep 30, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Management Discussion & Analysis
- Revenue $13,951.7 in FY2025, up 7.2% YoY from $13,008.9; driven by 4.4% organic growth, 2.5% acquisitions net of divestitures, 0.4% FX tailwind
- Operating margin 9.9% vs 8.4% YoY; cost of revenues fell to 71.2% vs 72.1%; SG&A fell to 15.9% vs 17.1% of revenue
- Best segment: Dx operating income $1,779.9 (+10.8% YoY), margin 16.4% vs 15.8%; BLS operating income $498.5 (+8.6%), margin 16.1% vs 15.7%
- Operating cash flow $1,640.5 vs $1,585.8; capex $434.5 (3.1% of revenue); dividends $240.7; share repurchase authorization remaining $830.4
- OBBBA legislation risk flagged: potential Medicaid/ACA coverage reduction; capex guided higher to ~4.0% of revenue in 2026; pending acquisitions (Empire City, Parkview) up to $415.0
Risk Factors
- Ravgen patent verdict: $272M jury award + $100M enhanced damages + $2.6M supplemental + $100/test ongoing royalty through patent life
- PAMA Medicare reimbursement cuts frozen 2026, resuming 2027–2029 capped at 15%/year with further reductions possible thereafter
- Senior notes $5.2B outstanding, $500M due within 12 months, plus $1.0B revolving credit facility with leverage ratio covenants
- FDA's April 2024 LDT final rule rescinded after legal challenge, but potential reissuance could impose device-level regulatory burden on core lab testing
- BLS dependent on specialized research animal supply; import restrictions or activist disruption could halt preclinical services with no short-term substitute
Business Overview
- Dual-segment lab services platform: Dx (clinical testing, $10.9B revenue) and BLS (drug development services, $3.1B revenue), total revenues $13.95B
- New specialty test launches in 2025: Alzheimer's disease diagnostics, molecular residual disease detection, expanded oncology precision testing; also nationwide self-collection HPV/STI testing via Labcorp OnDemand
- Strategic pivot toward health system partnerships (13 signed/completed in 2025) and international expansion via minority stake acquisition in SYNLAB, Europe's diagnostic services leader
- BLS supported 85% of FDA-approved drugs/therapeutic products in 2025; $582M deployed in acquisitions; $450M in share buybacks at avg $254.17/share
- Launched more than 130 new Dx tests in 2025 while expanding cell and gene therapy lab capacity in Madison, WI: targeting ~2,000 active global CGT clinical trials representing ~20% of biopharma pipelines
AI summary of the LH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $3,731.1, up 5.8% YoY from $3,527.3
- BLS strongest segment: revenue $836.2, up 6.5%; Dx revenue $2,900.7, up 5.5%
- Operating income $451.6, up 14.5%; cost margin 29.8% vs 29.7% YoY
- BLS operating margin 17.0% vs 15.7%; Dx margin 18.0% vs 17.6%
- Headwinds: OBBBA could reduce insurance coverage and diagnostics utilization; no material impact currently expected
Risk Factors
- No risk-factors section provided; supplied text covers share repurchases, insider trading arrangements, and exhibits
- Share repurchase authorization expanded to $1,378.6 million on July 8, 2026
- Quarterly repurchases totaled 1.3 million shares at average $260.30 per share
- Rule 10b5-1 arrangements covered planned sales of 1,178 and 3,000 shares through December 31, 2027 and August 10, 2027
AI summary of the LH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Q3 2026 results scheduled for October 28, 2026 before market open
- Management webcast at 9:00 a.m. ET to discuss quarterly results
Item EX-99.1: Item EX-99.1
- Third-quarter 2026 results scheduled for October 28, 2026, before market open
- Management webcast at 9:00 a.m. ET to discuss financial performance
Item 7.01: Regulation FD Disclosure
- CMS preliminary 2027–2029 rates imply steep annual PAMA reimbursement cuts, creating material pressure on Labcorp’s Medicare revenue and patient access
- Labcorp reaffirmed 2026–2029 outlook despite CMS proposal: 5%–8% revenue CAGR
Item 7.01: Regulation FD Disclosure
- 2026 Investor Day outlined Labcorp’s growth strategy, innovation roadmap, and long-term financial outlook through 2029
- Full-year 2026 guidance reaffirmed, reducing near-term guidance uncertainty
Item EX-99.1: Item EX-99.1
- Reaffirms 2026 revenue guidance of $14,710–$14,827 million and adjusted EPS of $18.10–$18.55
- 2026 free cash flow guidance remains $1,240–$1,360 million, supporting capital returns and investment
AI summaries of LH 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for LH
Don't miss the next LH filing
- Alerts as it files. A push when LH files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut LH, by share count.
- Ask anything. An AI agent that reads every LH filing and answers with sources.
LH alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Meltzer Jonathan C | A | Sep 1, 2026 | 900 | - |
| Oyegunwa Akinbolade | A | Sep 1, 2026 | 750 | - |
| Vaughn Bryan T | A | Sep 1, 2026 | 1,500 | - |
| Caveney Brian J | A | Sep 1, 2026 | 3,000 | - |
| ANDERSON KERRII B | Sell | Aug 17, 2026 | 3,000 | $318.02 |
| Schechter Adam H | Sell | Aug 11, 2026 | 4,669 | $320.37 |
| Summy Amy B. | Sell | Aug 4, 2026 | 924 | $306.74 |
| Wilkinson Peter J | Sell | Aug 3, 2026 | 1,338 | $309.23 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $13.0B | $14.0B |
| Gross Profit | - | $3.6B | $4.0B |
| Operating Income | - | $1.1B | $1.4B |
| Net Income | - | $746.0M | $876.5M |
| Gross Margin | - | 27.9% | 28.8% |
| Op. Margin | - | 8.4% | 9.9% |
| Net Margin | - | 5.7% | 6.3% |
| Balance Sheet | |||
| Total Assets | $16.7B | $18.4B | $18.4B |
| Equity | - | $8.1B | $8.6B |
| ROE | - | 9.3% | 10.2% |
| Per Share | |||
| EPS | - | $8.84 | $10.46 |
| Cash Flow | |||
| Operating CF | - | $1.6B | $1.6B |
| CapEx | $453.6M | $489.9M | $434.5M |
Source: XBRL data in Labcorp (LH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate LH share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 42 | $8.74B |
| Q1 2026 | 38 | $8.17B |
| Q4 2025 | 36 | $7.98B |
| Q3 2025 | 38 | $10.18B |
| Q2 2025 | 35 | $9.38B |
| Q1 2025 | 34 | $6.14B |
| Q4 2024 | 32 | $5.47B |
| Q3 2024 | 31 | $2.50B |
- FMR LLC (Fidelity)+616.5K (+48%)
- BlackRock+129.4K (+2%)
- Morgan Stanley+111.4K (+7%)
- Millennium Management+103.5K (+83%)
- Bank of America Corp+87.5K (+12%)
- JPMorgan Chase & Co−264.3K (-17%)
- Northern Trust−114.3K (-11%)
- Ameriprise Financial−81.3K (-44%)
- Invesco Ltd−78.5K (-6%)
- Citadel Advisors LLC−36.0K (-50%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 286 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
LH filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 30, 2026 | - | Analysis | - |
| 8-K | Sep 22, 2026 | - | Analysis | - |
| 8-K | Sep 10, 2026 | - | Analysis | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 8-K | Aug 28, 2026 | - | Analysis | - |
| 4 | Aug 18, 2026 | - | - | - |
| 8-K | Aug 17, 2026 | - | Analysis | - |
| 8-K | Aug 14, 2026 | - | Analysis | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 8-K | Jul 10, 2026 | - | Analysis | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 4 | Jun 10, 2026 | - | - | |
| 8-K | May 27, 2026 | - | Analysis | |
| 8-K | May 26, 2026 | - | Analysis | |
| 4 | May 13, 2026 | - | - | |
| 10-Q | May 4, 2026 | Mar 31, 2026 | Analysis |
Related Health Care companies
- CDNA · CareDx, Inc.Services-Medical Laboratories
- CSTL · CASTLE BIOSCIENCES INCServices-Medical Laboratories
- CELC · Celcuity Inc.Services-Medical Laboratories
- FTRE · Fortrea Holdings Inc.Services-Medical Laboratories
- FLGT · Fulgent Genetics, Inc.Services-Medical Laboratories
- GRAL · GRAIL, Inc.Services-Medical Laboratories
- GH · Guardant Health, Inc.Services-Medical Laboratories
- NTRA · Natera IncServices-Medical Laboratories
LH SEC filings: frequently asked questions
Are LH insiders buying or selling?
In the last 90 days, Labcorp (LH) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $3.2 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold LH stock?
As of June 30, 2026, the largest Labcorp (LH) holders among the 13F filers tracked by SignalX were BlackRock ($1.8 billion), Vanguard Capital Management LLC ($1.5 billion), State Street Corp ($1.1 billion), Vanguard Portfolio Management LLC ($1.0 billion), FMR LLC (Fidelity) ($533.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was LH's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Labcorp (LH) reported revenue of $14.0 billion (up 7.2% from FY2024) and net income of $876.5 million. Diluted EPS was $10.46. The figures come from the XBRL data in the 10-K.
What are the main risks in LH's latest 10-K?
In the 10-K filed February 24, 2026, Labcorp (LH) flagged: Ravgen patent verdict: $272M jury award + $100M enhanced damages + $2.6M supplemental + $100/test ongoing royalty through patent life. PAMA Medicare reimbursement cuts frozen 2026, resuming 2027–2029 capped at 15%/year with further reductions possible thereafter. (AI summary of the Risk Factors section.)
What did LH report in its latest 8-K?
Labcorp (LH) filed an 8-K on September 30, 2026 reporting Item 7.01 (Regulation FD Disclosure). Q3 2026 results scheduled for October 28, 2026 before market open.
What are the latest LH SEC filings?
Labcorp (LH) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 30, 2026 and a Form 4 insider filing on September 3, 2026.
What is LH's SEC CIK number?
Labcorp (LH)'s SEC Central Index Key (CIK) is 920148. EDGAR lists every LH filing under that number.
Ask anything about LH
The research agent reads LH's filings, financials, insider trades and 13F holders, then answers with sources.